Nanovibronix (NAOV) Stock Price, News & Analysis

Company Overview

Nanovibronix (NASDAQ: NAOV) is a medical technology company specializing in noninvasive therapeutic and surgical solutions powered by acoustic resonance. The company develops, manufactures and markets a range of ultrasound-based devices designed to address pain management, wound healing, urinary catheter-related infections and respiratory complications. By harnessing low-frequency ultrasound energy, Nanovibronix products aim to deliver targeted tissue stimulation that can accelerate healing processes and improve patient outcomes without the need for pharmaceuticals or invasive procedures.

The company’s flagship offerings include the Pain Relief System, which utilizes extracorporeal acoustic resonance to reduce inflammation and alleviate chronic and acute musculoskeletal discomfort. In its urology division, Nanovibronix markets the UroShield™ catheter, an embedded ultrasound-enabled indwelling catheter designed to inhibit biofilm formation and reduce the incidence of catheter-associated urinary tract infections. In respiratory care, the TrueWave™ therapy system provides airway clearance by transmitting vibration through endotracheal and tracheostomy tubes, helping to prevent ventilator-associated complications.

Founded in Israel, Nanovibronix has expanded its global footprint with operations and distribution channels across North America, Europe and parts of Asia. The company’s research and development activities are supported by a combination of internal laboratories and partnerships with academic institutions and clinical centers. Over the years, Nanovibronix has obtained regulatory approvals in key markets, including FDA clearance for multiple product lines and CE marking for distribution throughout the European Union.

Nanovibronix is led by a management team with extensive experience in medical device development, clinical research and regulatory affairs. The company’s board of directors includes seasoned executives from the healthcare and life sciences sectors. Looking ahead, Nanovibronix continues to pursue new therapeutic indications and strategic collaborations aimed at expanding its product portfolio and driving adoption of acoustic resonance technologies in mainstream medical practice.

Key Stats

• Today's Range: $0.95 to $1.08
• 50-Day Range: $0.81 to $4.11
• 52-Week Range: $0.67 to $16.25
• Volume: 9.36 million shs
• Average Volume: 1.88 million shs
• Market Capitalization: $2.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Nanovibronix Stock Analysis - MarketRank™

Nanovibronix scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Nanovibronix.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nanovibronix is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nanovibronix is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nanovibronix has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

44.80% of the float of Nanovibronix has been sold short.

Short Interest Ratio / Days to Cover

Nanovibronix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanovibronix has recently increased by 40.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanovibronix does not currently pay a dividend.

Dividend Growth

Nanovibronix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

44.80% of the float of Nanovibronix has been sold short.

Short Interest Ratio / Days to Cover

Nanovibronix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanovibronix has recently increased by 40.77%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Nanovibronix has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Nanovibronix this week, compared to 0 articles on an average week.

Search Interest

Only 4 people have searched for NAOV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Nanovibronix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanovibronix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.30% of the stock of Nanovibronix is held by insiders.

Percentage Held by Institutions

Only 16.39% of the stock of Nanovibronix is held by institutions.

NAOV Stock Analysis - Frequently Asked Questions

How have NAOV shares performed this year?

Nanovibronix's stock was trading at $6.49 on January 1st, 2025. Since then, NAOV stock has decreased by 84.4% and is now trading at $1.01.

How were Nanovibronix's earnings last quarter?

Nanovibronix, Inc. (NASDAQ:NAOV) announced its quarterly earnings data on Tuesday, May, 20th. The company reported ($3.98) EPS for the quarter. The firm earned $1.02 million during the quarter. Nanovibronix had a negative trailing twelve-month return on equity of 54.73% and a negative net margin of 210.82%.

When did Nanovibronix's stock split?

Nanovibronix's stock reverse split before market open on Friday, March 14th 2025.The 1-11 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

How do I buy shares of Nanovibronix?

Shares of NAOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nanovibronix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nanovibronix investors own include Exela Technologies (XELA), Assertio (ASRT), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO), Senseonics (SENS) and SNDL (SNDL).

Company Calendar

• Last Earnings: 5/20/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NAOV
• CIK: 1326706
• Web: www.nanovibronix.com
• Phone: (914) 233-3004
• Fax: 914-376-6111
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($13.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.70 million
• Net Margins: -210.82%
• Pretax Margin: -209.80%
• Return on Equity: -54.73%
• Return on Assets: -38.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.47
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: $2.56 million
• Price / Sales: 1.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.84 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 2,580,000
• Free Float: 2,422,000
• Market Cap: $2.61 million
• Optionable: Not Optionable
• Beta: 1.71